Lung Cancer Diagnosis and Therapeutics Market will experience a noticeable growth during the forecast period 2018 – 2023

Orion Market Research (OMR), recently published a market research report on Global Lung Cancer Diagnosis and Therapeutics Market. According to the OMR analysis, the global lung cancer diagnosis and therapeutics market is expected to grow significantly during forecast period due to rising prevalence of cancer disease, globally. The global lung cancer diagnosis and therapeutics market is segmented on the basis of type, therapy, diagnosis and end user.

For free sample request visit at: https://www.omrglobal.com/request-sample/?id=17418

The report provides detailed and insightful chapters on market overview, key findings, strategic recommendations, market estimations, market determinants, key company analysis, market share analysis, competitive landscape, company profiling, market segmentation, geographical analysis, analyst insights and predictive analysis of the market.

Over the last decades, an unprecedented change in human lifestyles has been observed. These lifestyles brought some major health challenges that lead to adverse effects on individuals. Smoking and tobacco are such major habits which are increasing the prevalence of various respiratory diseases and cancer. Smoking is the principal cause of lung cancer.

According to World Cancer Research Fund International, smoking is responsible for around 85% of all types of this cancer. Men who smoke are 23 times more likely to develop lung cancer. More than 1.8 million of new cases were diagnosed in 2012. An estimated 1.6 million deaths reported in 2012 which is extensively high when compared to 2002 deaths due to lung cancer. Approximately, 1.18 million deaths were recorded in 2002 which shows an increase of 34% over these years. About 58 percent of lung cancer cases accounted from less developed countries. Europe and North America recorded the maximum number of lung cancer incidences while Africa and, Latin America and Caribbean hold the lowest incidence of lung cancer.

Full report of global lung cancer diagnosis and therapeutics market is available at https://www.omrglobal.com/industry-reports/lung-cancer-diagnosis-market/

While, Hungary had the highest rate of lung cancer, followed by Serbia and Democratic People's Republic of Korea. Additionally, as per American Lung Association, geriatric population has the maximum probability to be detected with lung cancer. 83 % of lung cancer patients were 60 years of age or older in the year 2013. In Europe, more than 410,000 new cases of lung cancer were diagnosed in 2012.

Lung cancer is the third most common cancer in the UK during 2013-14. It accounts for 13% of all new cases. The region recorded approx. 46,400 new cases of lung cancer in 2014 and 130 cases diagnosed every day. Over the last decade, 4 percent increase in lung cancer incidence rates recorded. The key players in the lung cancer diagnosis and therapeutics market include AstraZeneca plc, Eli lilly and Sanofi-Aventis, Arqule Inc, Daiichi Sankyo co. Ltd, Celgene, Merck, Pfizer, Ventana, Roche, Genentech, Glaxosmith, Boehringer, Novartis, Bayer, Bristol-Myers Squibb, Eisai, AbbVie, Pharmacyclics.

Global lung cancer diagnosis and therapeutics market by region is segmented into North America, Europe, Asia pacific and rest of the world in which Asia pacific region is growing at a significant rate due to rising incidence and prevalence of cancer. North America is dominating this market as the major market leaders are situated in this region. North America holds the significant market share of the global lung cancer diagnosis and therapeutics market, followed by Europe.

Comprehensive research methodology of global lung cancer diagnosis and therapeutics:

This report also includes detailed and extensive market overview with key analyst insights.

• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the global lung cancer diagnosis and therapeutics
• Insights about market determinants which are stimulating the global lung cancer diagnosis and therapeutics
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +1 646-755-7667, +91 780-304-0404

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

This release was published on openPR.